Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638097 | 0.85 | MTNR1A (0.67) | MTNR1AMTNR1B | |
| SCHEMBL7281450 | 0.79 | MTNR1A (0.68) | MTNR1AMTNR1B | |
| SCHEMBL9376505 | 0.79 | CYP19A1 (0.56) | MTNR1AMTNR1BCYP19A1CYP1A2MAPT | |
| SCHEMBL15881462 | 0.76 | CYP19A1 (0.52) | MTNR1AMTNR1BCYP19A1CYP1A2MAPT | |
| SCHEMBL12635376 | 0.75 | MTNR1A (0.52) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL25604514 | 0.74 | MTNR1A (0.53) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL19962308 | 0.74 | CYP19A1 (0.59) | CYP19A1CHRM2CHRM1CHRM3 | |
| SCHEMBL12634890 | 0.73 | CHRM2 (0.60) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL6634278 | 0.73 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL6634680 | 0.73 | MTNR1A (0.52) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116593851-B | Test method and test system for MOS transistor gate oxide capacitance | CHANGXIN MEMORY TECHNOLOGIES, INC. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-116593851-A | Test method and test system for MOS transistor gate oxide capacitance | 长鑫存储技术有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-116593851-B | Test method and test system for MOS transistor gate oxide capacitance | CHANGXIN MEMORY TECHNOLOGIES, INC. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4502609-A2 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201604-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240390327-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | JOHNS HOPKINS UNIVERSITY (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024155777-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-11918557-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11845990-B2 | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | VANDA PHARMACEUTICALS INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-116593851-A | Test method and test system for MOS transistor gate oxide capacitance | 长鑫存储技术有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | VANDA PHARMACEUTICALS INC. | 2023-07-06 | — | — | US | disclosed |
| US-11633377-B2 | Treatment of circadian rhythm disorders | VANDA PHARMACEUTICALS INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11600045-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220366648-A1 | Collaborative Light Show Authoring for Tessellated Geometries | CONTRAVENTUM, LLC (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022183083-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-09-01 | — | — | WO | disclosed |
| US-11282276-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201604-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP19A1 732/4885 |
| US-20240156775-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP19A1 732/4885 |
| US-20230210810-A1 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP19A1 732/4885 |
| US-11845990-B2 | Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype | PER2, CRY1, NR1I3 | MTNR1A 13/4885MTNR1B 37/4885CYP19A1 1926/4885 |
| US-11633377-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP19A1 732/4885 |
| US-11918557-B2 | Treatment of circadian rhythm disorders | CRY1, PER2, CRY2 | MTNR1A 4/4885MTNR1B 5/4885CYP19A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.